Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2007-05-18 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: REIMS (51100), Marne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE POMMERY : revenue, balance sheet and financial ratios
SELAS PHARMACIE POMMERY is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in REIMS (51100),
this company of category PME
shows in 2023 a revenue of 2.1 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE POMMERY (SIREN 498078781)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
N/C
2 107 166 €
N/C
N/C
N/C
N/C
N/C
Net income
255 837 €
332 448 €
154 108 €
272 130 €
256 729 €
175 686 €
168 618 €
184 465 €
EBITDA
N/C
N/C
206 200 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
7.3%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELAS PHARMACIE POMMERY generates positive net income of 256 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 184 k€ -> 256 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
255 837 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 4%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 85%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
4.169%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
85.069%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
22.13
11.175
9.06
8.082
5.26
0.529
0.056
4.169
Financial autonomy
76.328
83.358
85.997
86.399
90.653
92.045
84.672
85.069
Repayment capacity
None
None
None
None
None
0.061
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
7.407%
None%
None%
Sector positioning
Debt ratio
4.172025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent
In 2025, the debt ratio of SELAS PHARMACIE POMMERY (4.17) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
85.07%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent+10 pts over 3 years
In 2025, the financial autonomy of SELAS PHARMACIE POMMERY (85.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.06 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of SELAS PHARMACIE POMMERY (0.06) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 183.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
403.752
392.405
524.479
594.253
937.502
203.923
151.52
183.212
Interest coverage
None
None
None
None
None
0.827
None
None
Sector positioning
Liquidity ratio
183.212025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good
In 2025, the liquidity ratio of SELAS PHARMACIE POMMERY (183.21) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.83x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELAS PHARMACIE POMMERY (0.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS PHARMACIE POMMERY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
135 996 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
24
0
0
Customer payment term (days)
0
0
0
0
0
3
0
0
Supplier payment term (days)
0
0
0
0
0
20
0
0
Positioning of SELAS PHARMACIE POMMERY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELAS PHARMACIE POMMERY is estimated at
4 064 001 €
(range 2 757 850€ - 6 376 977€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2757k€4064k€6376k€
4 064 001 €Range: 2 757 850€ - 6 376 977€
NAF 5 année 2025
Valuation method used
Net Income Multiple
255 837 €
×
15.9x
=4 064 001 €
Range: 2 757 850€ - 6 376 977€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE POMMERY with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE POMMERY
What is the revenue of SELAS PHARMACIE POMMERY ?
The revenue of SELAS PHARMACIE POMMERY in 2023 is 2.1 M€.
Is SELAS PHARMACIE POMMERY profitable?
Yes, SELAS PHARMACIE POMMERY generated a net profit of 256 k€ in 2025.
Where is the headquarters of SELAS PHARMACIE POMMERY ?
The headquarters of SELAS PHARMACIE POMMERY is located in REIMS (51100), in the department Marne.
Where to find the tax return of SELAS PHARMACIE POMMERY ?
The tax return of SELAS PHARMACIE POMMERY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE POMMERY operate?
SELAS PHARMACIE POMMERY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart